An Insight to Nanostructured Lipid Carrier System
In pharmaceutical field, many drugs are being invented to combat the existing new diseases. The winds of change in the drug scenario are blowing forcefully worldwide. The emergence of new technologies provides an unique opportunities to exploit novel approaches in drug delivery. A shift from conventional drug delivery to novel drug delivery is noticed as shift from conventional drug delivery suffers from various drawbacks, But these new mighty compounds in drug therapy solely are not sufficient to meet the today’s need. There is an urgent need for the smart technology, as the drugs available suffer from serious problems like poor solubility and poor bioavailability. Most of the drugs that are available therapeutically comes under BCS class II ie, poorly soluble and high lipophilc. To assure progress in drug therapy, the development of new drugs merely is not sufficient. Issues arising in delivery of new drugs should also be addressed. Thus there is an emergent need to improve the bioavailability of these drugs, the only remedy or boon for such drugs is the discovery of some smart technologies which can improve the bioavailability of these drugs. Nano drug delivery systems are the one such universal approach which fulfills the lacuna, which exists in conventional drug delivery systems. These Nano drug delivery systems, improves the pharmacokinetic profiles of many drugs. In 1980 K. Eric Drexler developed and popularized the concept of nanotechnology. In this review a deep insight on Nano structured lipid carriers is discussed elaborating its birth, significant qualities compared to other colloidal systems, its structure, characteristics, preparation and application are spotted.
Key words: BCS class, Lipophilic, Nano technology, Nano structured lipid carrier.
2. Scheffel U, Rhodes BA, Natajaran TK, Wagner HN “Albumin microspheres for study of the reticuloendothelial system”J Nucl Med. 1970; 13:498–503.
3. Jumaa M, Muller BW “Lipid emulsions as a novel system to reduce the hemolytic activity of lytic agents: Mechanism of protective effect” Eur J Pharm Sci. 2000; 9: 285–90.
4. Parashar AK, D. Chadhar KV, Devaliya R, Shrivastav V, Jain UK, “A review on Solid Lipid Nanoparticles (SLN) for controlled and targeted delivery of medicinal agents Current Research in Pharmaceutical Sciences” 2011; 02: 37-47.
5. Manjunath K, Venkateswarlu V. “Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release” 2005, 107:215–28.
6. Siekmann B, Westesen K. “Submicron-sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett”1992, 1:123–6
7. Müller RH, Keck CM. “Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles” J Biotech, 2004; 113:151–70.
8. Muller RH, Mäder K, Gohla S “Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm” 2000; 50:161–77
9. Diederichs JE, Muller RH “Liposomes in cosmetics and pharmaceuti-cal products. Pharm Indones” 1994; 56: 267–75.
10. Freitas C, Müller RH “Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles (SLN) dispersions” Int J Pharm 1998; 168: 221–9.
11. Muller RH, Mäder K, Gohla S. “Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art” Eur J Pharm Biopharm 2000; 50: 161–77.
12. Muller RH, Mehnert W, Lucks JS, Schwarz C, Muhlen AZ, Weyhers H “Solid lipid nanoparticles (SLN)-alternative colloidal carrier systems for controlled drug delivery” Eur J Pharm Biopharm 1995; 41:62–9.
13. Cavalli R, Caputo O, Gasco MR “Solid lipospheres of doxorubicin and idarubicin” Int J Pharm 1993; 89: R9-R12.
14. Allen DD, Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ “Brain uptake of thiamine-coated nanoparticles” J Controlled Release 2003; 93: 271–82.
15. Dingler A “Feste lipid-nano patikelals colloidal works off trager system zur dermalen applikation, in PhD thesis” Berlin; 1998.
16. Fundaro A, Cavalli R, Bagoni A, Vighetto D, Zara GP, Gasco MR “Non-stealth and stealth solid lipid nanoparticles(sln) carrying doxorubicin: pharmacokinetic and tissue distribution after i. v. administration to rats” Pharm Res 2000; 42:337–43.
17. Chen D, Yang T, Liang W, Zhang Q “In vitro and in vivo study of two types of long circulating solid lipid nanoparticles containing paclitaxel” Chem Pharm Bull 2001; 49:1444–7.
18. Reddy JS, Venkateshwarlu V “Novel delivery systems for drug targeting to the brain” Drugs Future 2004; 29:63–83.
19. Wang JX, Sun X, Zhang ZR “Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles” Eur J Pharm Biopharm 2002; 54:285–90
20. Siekmann B, Westesen K “Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions” Eur J Pharm Biopharm 1996; 43:104-9.
21. Sarangi MK, Padhi S, “Solid Lipid Nanoparticles–A Review” Journal of Critical Reviews 2016; 3(3):5-12.
22. Yener MUG, “Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives” International Journal of Nanomedicine 2007; 2(3):289–300.
23. Mukherjee S, Ray. S, Thakur R. S “Solid lipid nanoparticles: A modern formulation approach in drug delivery system” Indian J Pharm Sci. 2009; 71(4):349-358.
24. Müller RH, Radtke M, Wissing SA “Nanostructured lipid matrices for improved microencapsulation of drugs” Int J Pharm 2002; 242:121-128.
25. Radtke M, Müller RH “Nanostructured Lipid Carriers: A novel generation of solid lipid drug drug Carriers” Pharmaceutical Technology Europe 1991; 17:1-4
26. Charcosset C, El-Harati A, Fessi H “Preparation of solid lipid nanoparticles using a membrane contactor” J Control Release , 2005; 108:112-120.
27. Kaur S, Nautyal U, Singh R, Singh S, Devi A. “Nanostructure Lipid Carrier (Nlc): The New Generation Of Lipid Nanoparticles” Asian Pacific Journal Of Health Sciences, 2015; 2(2):76-93.
28. Zhuang C Ning Li, Mi Wang, Xiao-Ning Zhang, Wei-San Pan, Jun-Jie Peng, Yu-Sheng Pan, Xin Tang “Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability” Int J Pharm. 2010; 394(1-2):179-185.
29. Tiwari R, Pathak K. “Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics, and tissue uptake”, Int J Pharm. 2011; 415(1-2):232-43.
30. Peddinti S “Nanostructured lipid carriers as a drug carrier” J Pharm Nanotechnol Nanostruc 2016; 4:68-74.
31. Araújo J, Gonzalez E , Egea MA , Garcia ML , Souto EB , “Nanomedicinesfor ocular NSAIDs: safety on drug delivery” Nanomedicine. 2009; 5:394 – 401
32. Müller RH, Runge SA, Ravelli V. German Patent Application DE 19819273 A1; 1998
33. H. Bunjes, K.Westesen and M.H Koch, “Crystallization tendency and polymorphic transition in triglyceride nanoparticles” Int. J. Pharm, 1996; 129:159–173.
34. Patidar A, Thakur D, Kumar P and Verma J, “A review on Novel Lipid based Nanocarrier”, International Jouranal of Pharmacy and Pharmacetical Science, 2010; 2(2):30-35.
35. Tamjidi F, Shahedi M, Varshosaz J et al. Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules.Innov. Food Sci. Emerg. Technol. 2013; 19:29–43.
36. Araújo J , Gonzalez E , Egea MA , Garcia ML ,Souto EB., Nanomedicinesfor ocular NSAIDs: safety on drug delivery Nanomedicine. 2009; 5:394 – 401.
37. Schafer-Korting M , Mehnert W , Korting HC., Lipid nanoparticles for improved topical application of drugs for skin diseases . Adv Drug Deliv Rev.2007; 59:427-443.
38. Radtke M, Muller RH “Nanostructured lipid carriers: the new generation of lipid drug carriers” New Drugs, 2001; 2: 48–52.
39. Jenning V, Thu‥nemann AF, Gohla SH “Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids” Int J Pharm ,2000;199: 167–177.
40. Müller R.H. et al., German patent application 2000; 199(45):203.2.
41. Müller R.H. et al., extended patent on the basis of (6), PCT application PCT/EP00/04112 (2000). Drug release heading references.
42. Tamjidi F, Shahedi M, Varshosaz J, “Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules” Innov. Food Sci. Emerg.Technol; 2013; 19:29–43.
43. Ranpise NS, Korabu SS, Ghodake VN. ‘Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride”. Colloids Surf. B Biointerfaces, 2014; 116:81–87.
44. Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J “Nanostructured lipid carriers system: recent advances in drug delivery” J Drug Target. 2012; 20(10):813-830.
45. Fang CL, Al-Suwayeh SA, Fang JY “Nanostructured lipid carriers (NLCs) for drug delivery and targeting” Recent Pat Nanotechnol. 2013; 7(1):41-55.
46. Tran T.H, Ramasamy T, Truong D.H, Choi H.G, Yong C.S, Kim J.O “Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement”. AAPS Pharm.Sci. Tech, 2014; 15(6):1509–1515.
47. Chen CC, Tsai TH, Huang ZR, Fang JY, “Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics”, Eur. J. Pharm. Biopharm, 2010; 74(3), 474–482.
48. Triplett MD, Rathman JF. Optimization of β-carotene loaded solid lipid nanoparticles preparation using a high shear homogenization technique. J. Nanopart. Res. 2008; 11(3):601–614.
49. Hejri A, Khosravi A, Gharanjig K Hejazi M, “Optimisation of the formulation of beta-carotene loaded nanostructured lipid carriers prepared by solvent diffusion method” Food Chem. 2013; 141(1):117–123.
50. Tan SW, Billa N, Roberts CR, Burley JC, “Surfactant effects on the physical characteristics of amphotericin B-containing nanostructured lipid carriers” Colloids Surf. A Physicochem. Eng. Asp. 2010; 372(1–3):73–79.
51. Müller RH, Radtke M., Wissing SA, “Nanostructured lipid matrices for improved microencapsulation of drugs” Int. J. Pharm.2002; 242:121- 128.
52. Magdalene Radtke, Eliana B. Souto, Rainer H. Müller, “Nanostructured Lipid Carriers: A Novel Generation of Solid Lipid Drug Carriers”, Pharmaceutical Technology Europe, 2005; 17(4):45–50.
53. Dhruv K. Purohit, Tanaji D. Nandgude, Sushilkumar S. Poddar, “Nano-lipid Carriers for Topical Application: Current Scenario” Asian Journal of Pharmaceutics, 2016; (5):S3-S9.
54. Santos Maia C, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, Schafer Korting M “Drug targeting by solid lipid nanoparticles for dermal use” J Drug Target 2002; 10:489-95.
55. Pouton CW, Porter CJ “Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies” Adv Drug Deliv Rev 2008; 60:625-637.
56. Miteva D, Joseph M Rutkowski, J Brandon Dixon, Witold Kilarski, Jacqueline D Shields, Melody A Swartz, “Transmural flow modulates cell and fluid transport functions of lymphatic endothelium” Circ Res, 2010; 106:920-931.
57. Iqbal J, Hussain M. “Intestinal Lipid Absorption” Am J Physiol Endocrinol Metab. 2009; 296(6):E1183-94.
58. Porter C, Natalie L Trevaskis, William N Charman “Lipid and lipid-based formulations: optimizing the oral delivery of lipophilic drugs” Nat Rev Drug Discov. 2007; 6:231.
59. Walker J, Anthony R. Odden, JeyaseelanS Zhang P , Gregory J. Bagby ,Steve Nelson, and Kyle I. Happel “Ethanol exposure impairs LPS-induced pulmonary LIX expression: alveolar epithelial cell dysfunction as a consequence of acute intoxication” Alcohol Clin Exp Res. 2009; 33:357.
60. Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, Hoof BV, Raoof AR “Absorption, metabolism, and excretion of darunavir: a new protease inhibitor administered alone and with low dose ritonavir in healthy subjects” Drug Metab Dispos. 2009; 37:809.
61. Bhalekar M, Upadhaya P , Ashwini R Madgulkar , Sanjay J Kshirsagar , Akanksha Dube , Utkarsh S Bartakke “In-vivo bioavailability and lymphatic uptake evaluation for lipid nanoparticulates of darunavir”, Drug Deliv; 2016; 23(7):2581.
62. Pandey P, Sharma A, and Gupta U “Blood brain barrier: an overview on strategies in drug delivery, realistic in-vitro modeling and in vivo live tracking”, Tissue Barriers. 2016; (4):1, e1129476-1.
63. Radtke M, Müller RH “Stability study of creams containing cyclosporine SLN™. Drug Release from NLCs” Int Symp Control Rel Bioact Mater 2001; 28:472–473.
64. Banerjee D, Lao JY, Wang DZ, Huang JY, Ren ZF “Large-quantity free-standing ZnO nanowires”. Appl Phys Lett, 2003; 83:2061.
65. Karuppasamy A, Subrahmanyam A, “Effect of electron bombardment on the properties of ZnO thin films” 2007, Mater Lett; 61(4-5):1256-1259.
66. Pearton SJ, Norton DP, Ip K, Heo YW, Steiner T “Recent progress in processing and properties of ZnO” Prog Mater Sci, 2007; 50(3):293-340.
67. Ozgüra U, Alivov YI, Liu C, Tekeb A, Reshchikov MA “A comprehensive review of ZnO materials and devices” Journal of Applied Physics , 2005; 98:041301.
68. Lim SJ, Soon JK, Hyungjun K “High performance thin film transistor with low temperature atomic layer deposition nitrogen-doped ZnO” Appl Phys Lett 2007; 91:183517.
69. El Bekkaye Yousfi, Jacques F, Daniel L “Study of atomic layer epitaxy of zinc oxide by in-situ quartz crystal microgravimetry” Applied Surface Science, 2000; 153(4):223-234.
70. Seong KK, Cheol SH, Sang HK, Sun JY “Comparison between ZnO films grown by atomic layer deposition using H2O or O3 as oxidant” Thin Solid Films, 2005; 478(1-2):103-108.
71. Natarajan. J, Karri VVSR and Anindita De “Nano structured Lipid carrier: A Promising Drug delivery system” Global Journal of Nano medicine, 2017; 1(5):1-5.
72. Chandana KV, Guta VN, Kanna S, “Nano structured Lipid carriers: The frontiers in drug delivery”Asian Journal of pharmaceutical and clinical research, 2019; 12(7):8-12.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).